Gamma/Delta T-cell Functional Responses Differ After Pathogenic Human Immunodeficiency Virus and Nonpathogenic Simian Immunodeficiency Virus Infections
Overview
Authors
Affiliations
The objective of this study was to functionally assess gamma/delta (gammadelta) T cells following pathogenic human immunodeficiency virus (HIV) infection of humans and nonpathogenic simian immunodeficiency virus (SIV) infection of sooty mangabeys. gammadelta T cells were obtained from peripheral blood samples from patients and sooty mangabeys that exhibited either a CD4-healthy (>200 CD4(+) T cells/mul blood) or CD4-low (<200 CD4 cells/mul blood) phenotype. Cytokine flow cytometry was utilized to assess production of Th1 cytokines tumor necrosis factor alpha and gamma interferon following ex vivo stimulation with either phorbol myristate acetate/ionomycin or the Vdelta2 gammadelta T-cell receptor agonist isopentenyl pyrophosphate. Sooty mangabeys were observed to have higher percentages of gammadelta T cells in their peripheral blood than humans did. Following stimulation, gammadelta T cells from SIV-positive (SIV(+)) mangabeys maintained or increased their ability to express the Th1 cytokines regardless of CD4(+) T-cell levels. In contrast, HIV-positive (HIV(+)) patients exhibited a decreased percentage of gammadelta T cells expressing Th1 cytokines following stimulation. This dysfunction is primarily within the Vdelta2(+) gammadelta T-cell subset which incurred both a decreased overall level in the blood and a reduced Th1 cytokine production. Patients treated with highly active antiretroviral therapy exhibited a partial restoration in their gammadelta T-cell Th1 cytokine response that was intermediate between the responses of the uninfected and HIV(+) patients. The SIV(+) sooty mangabey natural hosts, which do not proceed to clinical AIDS, provide evidence that gammadelta T-cell dysfunction occurs in HIV(+) patients and may contribute to HIV disease progression.
Viremic non-progression in HIV/SIV infection: A tied game between virus and host.
Bayon-Gil A, Martinez-Picado J, Puertas M Cell Rep Med. 2025; 6(1):101921.
PMID: 39842407 PMC: 11866547. DOI: 10.1016/j.xcrm.2024.101921.
Field K, Wragg K, Kent S, Lee W, Juno J Clin Transl Immunology. 2024; 13(2):e1486.
PMID: 38299190 PMC: 10825377. DOI: 10.1002/cti2.1486.
Residual immune dysfunction under antiretroviral therapy.
Cai C, Sereti I Semin Immunol. 2021; 51:101471.
PMID: 33674177 PMC: 8410879. DOI: 10.1016/j.smim.2021.101471.
Clohosey M, Mann B, Ryan P, Apanasovich T, Maggirwar S, Pennington D Cells. 2020; 9(12).
PMID: 33271808 PMC: 7760715. DOI: 10.3390/cells9122568.
Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells.
Lehmann N, Paret C, El Malki K, Russo A, Neu M, Wingerter A Front Immunol. 2020; 11:1819.
PMID: 32973759 PMC: 7468390. DOI: 10.3389/fimmu.2020.01819.